Published in BMJ on April 15, 1995
Comparing treatments. BMJ (1995) 3.02
Sharing resources to create a district drug formulary: a countywide controlled trial. Br J Gen Pract (1996) 1.33
Lessons from international experience in controlling pharmaceutical expenditure. III: Regulating industry. BMJ (1996) 1.30
The ethics of complementary medicine. J Med Ethics (1996) 0.87
Promoting cost effective prescribing. Cost effectiveness studies may not be cost effective. BMJ (1995) 0.85
Promoting cost effective prescribing. More trials from general practice are needed. BMJ (1995) 0.75
Current trends in the cardiovascular clinical trial arena (I). Curr Control Trials Cardiovasc Med (2004) 0.75
Promoting cost effective prescribing. Cost effectiveness rapidly becomes cost containment. BMJ (1995) 0.75
The UK pharmaceutical market. An overview. Pharmacoeconomics (1996) 0.75
An analysis of the influence of framework aspects on the study design of health economic modeling evaluations. Eur J Health Econ (2011) 0.75
A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction. JAMA (1992) 22.27
The scandal of poor medical research. BMJ (1994) 11.58
Rationale for systematic reviews. BMJ (1994) 7.90
Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Control Clin Trials (1989) 6.48
Prescribing selective serotonin reuptake inhibitors as strategy for prevention of suicide. BMJ (1994) 4.67
What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry (1994) 4.37
Assessing the clinical effectiveness of preventive maneuvers: analytic principles and systematic methods in reviewing evidence and developing clinical practice recommendations. A report by the Canadian Task Force on the Periodic Health Examination. J Clin Epidemiol (1990) 3.88
The cost-benefit approach. Br Med Bull (1974) 3.34
Something rotten in the state of clinical and economic evaluations? Health Econ (1994) 2.50
Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. N Engl J Med (1991) 2.46
The pharmaceutical industry and health reform: lessons from Europe. Health Aff (Millwood) (1994) 1.81
The use of statins: a case of misleading priorities? BMJ (1997) 13.35
Coverage by the news media of the benefits and risks of medications. N Engl J Med (2000) 7.50
Educational outreach visits: effects on professional practice and health care outcomes. Cochrane Database Syst Rev (2007) 7.25
Continuing education meetings and workshops: effects on professional practice and health care outcomes. Cochrane Database Syst Rev (2001) 7.24
Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ (1993) 7.14
Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ (2000) 6.67
Regulating the pharmaceutical industry. BMJ (1997) 6.61
Developing and implementing clinical practice guidelines. Qual Health Care (1995) 6.52
WITHDRAWN: Treatment discontinuation with selective serotonin reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs). Cochrane Database Syst Rev (2007) 6.02
Rationing health care. BMJ (1996) 5.27
Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet (1998) 4.54
North of England evidence based guidelines development project: guideline for the primary care management of dementia. BMJ (1998) 4.39
The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J (2003) 4.09
Inhalation vs. aspiration of single-walled carbon nanotubes in C57BL/6 mice: inflammation, fibrosis, oxidative stress, and mutagenesis. Am J Physiol Lung Cell Mol Physiol (2008) 3.80
North of England evidence based guidelines development project: methods of developing guidelines for efficient drug use in primary care. BMJ (1998) 3.14
Cooperative partnerships or conflict-of-interest? A national survey of interaction between the pharmaceutical industry and medical organizations. Intern Med J (2005) 3.08
Educational outreach visits: effects on professional practice and health care outcomes. Cochrane Database Syst Rev (2000) 3.04
Comparing treatments. BMJ (1995) 3.02
Social deprivation and prognostic benefits of cardiac surgery: observational study of 44 902 patients from five hospitals over 10 years. BMJ (2009) 2.95
A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med (1995) 2.88
Can general practitioners counsel? J R Coll Gen Pract (1989) 2.88
The doctor, the patient, and their contract. III. Alternative contracts: are they viable? Br Med J (Clin Res Ed) (1986) 2.86
The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J (2003) 2.78
Cimetidine and tranexamic acid in the treatment of acute upper-gastrointestinal-tract bleeding. N Engl J Med (1983) 2.72
The doctor, the patient, and their contract. I. The general practitioner's contract: why change it? Br Med J (Clin Res Ed) (1986) 2.70
Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med (2000) 2.68
Identification and population structure of Burkholderia stabilis sp. nov. (formerly Burkholderia cepacia genomovar IV). J Clin Microbiol (2000) 2.63
Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet (2002) 2.61
Efficacy of tricyclic drugs in treating child and adolescent depression: a meta-analysis. BMJ (1995) 2.61
The effects of information framing on the practices of physicians. J Gen Intern Med (1999) 2.52
Something rotten in the state of clinical and economic evaluations? Health Econ (1994) 2.50
Rewarding healthcare teams. BMJ (1998) 2.47
The doctor, the patient, and their contract. II. A good practice allowance: is it feasible? Br Med J (Clin Res Ed) (1986) 2.36
Applying resource allocation formulae to constituent parts of the U.K. Lancet (1980) 2.34
Local opinion leaders: effects on professional practice and health care outcomes. Cochrane Database Syst Rev (2000) 2.33
On the way to Calvary. Ministers should realise the command and control model the white paper entails. BMJ (1998) 2.30
Burkholderia ambifaria sp. nov., a novel member of the Burkholderia cepacia complex including biocontrol and cystic fibrosis-related isolates. Int J Syst Evol Microbiol (2001) 2.27
Wrong SIGN, NICE mess: is national guidance distorting allocation of resources? BMJ (2001) 2.19
Disease mongering: expanding the boundaries of treatable disease. Intern Med J (2008) 2.19
EUR-ASSESS Project Subgroup Report on Dissemination and Impact. Int J Technol Assess Health Care (1997) 2.18
Some guidelines on the use of cost effectiveness league tables. BMJ (1993) 2.16
Effects on quality of life with comprehensive rehabilitation after acute myocardial infarction. Am J Cardiol (1991) 2.13
Randomised controlled trial of effect of feedback on general practitioners' prescribing in Australia. BMJ (1999) 2.11
Data Note--9. Measuring the social costs of addictive substances. Br J Addict (1987) 2.09
When is it cost-effective to change the behavior of health professionals? JAMA (2001) 2.08
Failure of long surviving, passively enhanced kidney allografts to provoke T-dependent alloimmunity. I. Retransplantation of (AS X AUG)F1 kidneys into secondary AS recipients. J Exp Med (1979) 1.88
Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections. J Infect Dis (1999) 1.87
Autologous transfusion techniques: a systematic review of their efficacy. Transfus Med (2004) 1.84
The evidence for beta blockers in heart failure. BMJ (1999) 1.84
Audit and feedback versus alternative strategies: effects on professional practice and health care outcomes. Cochrane Database Syst Rev (2000) 1.79
Computer support for determining drug dose: systematic review and meta-analysis. BMJ (1999) 1.79
Efficiency in the National Health Service: lessons from abroad. Health Policy (1988) 1.79
Association between availability of non-prescription beta 2 agonist inhalers and undertreatment of asthma. BMJ (1993) 1.76
Perindopril for elderly people with chronic heart failure: the PEP-CHF study. The PEP investigators. Eur J Heart Fail (1999) 1.75
Cost-effectiveness league tables: more harm than good? Soc Sci Med (1993) 1.74
Economics of treatment of depression. Br J Psychiatry (1995) 1.74
Ethics and evidence based medicine. BMJ (1998) 1.74
Implantation of cardiac resynchronization therapy systems in the CARE-HF trial: procedural success rate and safety. Europace (2007) 1.73
Economic aspects of tobacco use and taxation policy. BMJ (1988) 1.70
A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med (1996) 1.64
Doctors have no time for alcohol screening. Br Med J (Clin Res Ed) (1987) 1.63
Burkholderia cepacia genomovar VI, a new member of the Burkholderia cepacia complex isolated from cystic fibrosis patients. Int J Syst Evol Microbiol (2001) 1.61
Development of a composite endpoint for randomized controlled trials in liver surgery. Br J Surg (2011) 1.58
Private finance for the public good? BMJ (1996) 1.56
"No thank you": why elderly patients declined to participate in a research study. Pharm World Sci (2001) 1.56
Catecholamines in fetal and newborn rat brain. J Neurochem (1973) 1.55
Audit and feedback: effects on professional practice and health care outcomes. Cochrane Database Syst Rev (2000) 1.53
Modelling prognostic factors in advanced pancreatic cancer. Br J Cancer (2008) 1.53
A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression. Cancer Invest (1998) 1.51
Clinical comparison of isolator and BACTEC 660 resin media for blood culture. J Clin Microbiol (1990) 1.51
Mass media interventions: effects on health services utilisation. Cochrane Database Syst Rev (2000) 1.50
Lessons from international experience in controlling pharmaceutical expenditure. II: Influencing doctors. BMJ (1996) 1.50
The CARE-HF study (CArdiac REsynchronisation in Heart Failure study): rationale, design and end-points. Eur J Heart Fail (2001) 1.49
SSRIs versus other antidepressants for depressive disorder. Cochrane Database Syst Rev (2000) 1.48
Aspirin and acute myocardial infarction: clarifying the message. Br J Gen Pract (1995) 1.48
Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer (2010) 1.46
Economic evaluation of cardiac rehabilitation soon after acute myocardial infarction. Am J Cardiol (1993) 1.44
Effectiveness of sumatriptan in reducing productivity loss due to migraine: results of a randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc (2000) 1.44
CONSORT: an important step toward evidence-based health care. Consolidated Standards of Reporting Trials. Ann Intern Med (1997) 1.43
Cloning and characterization of a Na+-driven anion exchanger (NDAE1). A new bicarbonate transporter. J Biol Chem (2000) 1.42
Trial of streptokinase in ischaemic stroke. Lancet (1995) 1.42
Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis (1995) 1.41
Regional distribution of family practitioner services: implications for National Health Service equity and efficiency. J R Coll Gen Pract (1987) 1.41
Spatiotemporal evolution of Poiseuille-Rayleigh-Bénard flows in binary fluids with Soret effect under initial pulselike disturbances. Phys Rev E Stat Nonlin Soft Matter Phys (2009) 1.40
Short-term treatment with zanamivir to prevent influenza: results of a placebo-controlled study. Clin Infect Dis (2000) 1.40
Cost-effectiveness of non-steroidal anti-inflammatory drugs (NSAIDs)-what makes a NSAID good value for money? Rheumatology (Oxford) (2000) 1.38
Computerised advice on drug dosage to improve prescribing practice. Cochrane Database Syst Rev (2001) 1.38
Patterns of psychopathology among urban poor children: comorbidity and aggression effects. J Consult Clin Psychol (1996) 1.34
Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence. Cochrane Database Syst Rev (2000) 1.33
The costs of alcohol misuse. Br J Addict (1985) 1.32
Comparative evaluation of four systems for determining susceptibility of gram-positive organisms. J Clin Microbiol (1986) 1.32
Lessons from international experience in controlling pharmaceutical expenditure. III: Regulating industry. BMJ (1996) 1.30